Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Ritsuko Iwanaga

TitleResearch Associate
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-OB/GYN RS GENERAL OPS

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Zhou Y, Nakajima R, Shirasawa M, Fikriyanti M, Zhao L, Iwanaga R, Bradford AP, Kurayoshi K, Araki K, Ohtani K. Expanding Roles of the E2F-RB-p53 Pathway in Tumor Suppression. Biology (Basel). 2023 Dec 11; 12(12). PMID: 38132337.
      View in: PubMed
    2. Brubaker LW, Backos DS, Nguyen VT, Reigan P, Yamamoto TM, Woodruff ER, Iwanaga R, Wempe MF, Kumar V, Persenaire C, Watson ZL, Bitler BG. Novel chromobox 2 inhibitory peptide decreases tumor progression. Expert Opin Ther Targets. 2023 Apr-May; 27(4-5):361-371. PMID: 37243607.
      View in: PubMed
    3. Nakajima R, Deguchi R, Komori H, Zhao L, Zhou Y, Shirasawa M, Angelina A, Goto Y, Tohjo F, Nakahashi K, Nakata K, Iwanaga R, Bradford AP, Araki K, Warita T, Ohtani K. The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F. Biochem Biophys Res Commun. 2023 06 30; 663:154-162. PMID: 37141667.
      View in: PubMed
    4. Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, Jeong AD, Guntupalli SR, Behbakht K, Gbaja V, Arnoult N, Chuong EB, Bitler BG. Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models. bioRxiv. 2023 Feb 23. PMID: 36865165.
      View in: PubMed
    5. Nakajima R, Zhao L, Zhou Y, Shirasawa M, Uchida A, Murakawa H, Fikriyanti M, Iwanaga R, Bradford AP, Araki K, Warita T, Ohtani K. Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool. Genes (Basel). 2023 02 02; 14(2). PMID: 36833320.
      View in: PubMed
    6. Iwanaga R, Truong BT, Hsu JY, Lambert KA, Vyas R, Orlicky D, Shellman YG, Tan AC, Ceol C, Artinger KB. Loss of prdm1a accelerates melanoma onset and progression. Mol Carcinog. 2020 09; 59(9):1052-1063. PMID: 32562448.
      View in: PubMed
    7. Komori H, Goto Y, Kurayoshi K, Ozono E, Iwanaga R, Bradford AP, Araki K, Ohtani K. Differential requirement for dimerization partner DP between E2F-dependent activation of tumor suppressor and growth-related genes. Sci Rep. 2018 05 31; 8(1):8438. PMID: 29855511.
      View in: PubMed
    8. Kurayoshi K, Shiromoto A, Ozono E, Iwanaga R, Bradford AP, Araki K, Ohtani K. Ectopic expression of the CDK inhibitor p21Cip1 enhances deregulated E2F activity and increases cancer cell-specific cytotoxic gene expression mediated by the ARF tumor suppressor promoter. Biochem Biophys Res Commun. 2017 01 29; 483(1):107-114. PMID: 28042030.
      View in: PubMed
    9. Kurayoshi K, Okuno J, Ozono E, Iwanaga R, Bradford AP, Kugawa K, Araki K, Ohtani K. The phosphatidyl inositol 3 kinase pathway does not suppress activation of the ARF and BIM genes by deregulated E2F1 activity. Biochem Biophys Res Commun. 2017 Jan 22; 482(4):784-790. PMID: 27888102.
      View in: PubMed
    10. Iwanaga R, Orlicky DJ, Arnett J, Guess MK, Hurt KJ, Connell KA. Comparative histology of mouse, rat, and human pelvic ligaments. Int Urogynecol J. 2016 Nov; 27(11):1697-1704. PMID: 27091643.
      View in: PubMed
    11. Kitamura H, Ozono E, Iwanaga R, Bradford AP, Okuno J, Shimizu E, Kurayoshi K, Kugawa K, Toh H, Ohtani K. Identification of novel target genes specifically activated by deregulated E2F in human normal fibroblasts. Genes Cells. 2015 Sep; 20(9):739-57. PMID: 26201719.
      View in: PubMed
    12. Wang CA, Harrell JC, Iwanaga R, Jedlicka P, Ford HL. Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3. Breast Cancer Res. 2014 Oct 30; 16(5):462. PMID: 25358638.
      View in: PubMed
    13. Kurayoshi K, Ozono E, Iwanaga R, Bradford AP, Komori H, Ohtani K. Cancer cell specific cytotoxic gene expression mediated by ARF tumor suppressor promoter constructs. Biochem Biophys Res Commun. 2014 Jul 18; 450(1):240-6. PMID: 24893334.
      View in: PubMed
    14. Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res. 2012 Jul 05; 14(4):R100. PMID: 22765220.
      View in: PubMed
    15. Ozono E, Komori H, Iwanaga R, Tanaka T, Sakae T, Kitamura H, Yamaoka S, Ohtani K. Tumor suppressor TAp73 gene specifically responds to deregulated E2F activity in human normal fibroblasts. Genes Cells. 2012 Aug; 17(8):660-72. PMID: 22702391.
      View in: PubMed
    16. Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K. Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer. Gynecol Oncol. 2012 May; 125(2):451-7. PMID: 22333994.
      View in: PubMed
    17. McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest. 2009 Sep; 119(9):2663-77. PMID: 19726883.
      View in: PubMed
    18. Ozono E, Komori H, Iwanaga R, Ikeda MA, Iseki S, Ohtani K. E2F-like elements in p27(Kip1) promoter specifically sense deregulated E2F activity. Genes Cells. 2009 Jan; 14(1):89-99. PMID: 19077036.
      View in: PubMed
    19. Komori H, Enomoto M, Nakamura M, Iwanaga R, Ohtani K. Distinct E2F-mediated transcriptional program regulates p14ARF gene expression. EMBO J. 2005 Nov 02; 24(21):3724-36. PMID: 16211008.
      View in: PubMed
    20. Matsumura-Arioka Y, Ohtani K, Hara T, Iwanaga R, Nakamura M. Identification of two distinct elements mediating activation of telomerase (hTERT) gene expression in association with cell growth in human T cells. Int Immunol. 2005 Feb; 17(2):207-15. PMID: 15629899.
      View in: PubMed
    21. Iwanaga R, Komori H, Ohtani K. Differential regulation of expression of the mammalian DNA repair genes by growth stimulation. Oncogene. 2004 Nov 11; 23(53):8581-90. PMID: 15467751.
      View in: PubMed
    Iwanaga's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)